Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROOF 302 adjuvant infigratinib in FGFR3-altered invasive urothelial carcinoma
NL-OMON55032Phase 3Completed
- Sponsor
- QED Therapeutics
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Infigratinib with Placebo (2 arms). Primary endpoint: Centrally reviewed disease-free survival. Started Mar 2020; status: completed.
02
Drugs
infigratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON55032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55032.